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Abstract 
Epstein Barr virus (EBV) was the first human tumor virus being discovered and remains 
to date the only human pathogen that can transform cells in vitro. 55 years of EBV 
research have now brought us to the brink of an EBV vaccine. For this purpose, 
recombinant viral vectors and their heterologous prime-boost vaccinations, EBV derived 
virus-like particles and viral envelope glycoprotein formulations are explored and are 
discussed in this review. Even so cell-mediated immune control by cytotoxic 
lymphocytes protects healthy virus carriers from EBV associated malignancies, 
antibodies might be able to prevent symptomatic primary infection, the most likely EBV 
associated pathology against which EBV vaccines will be initially tested. Thus, the 
variety of EBV vaccines reflects the sophisticated life cycle of this human tumor virus 
and only vaccination in humans will finally be able to reveal the efficacy of these 
candidates. Nevertheless, the recently renewed efforts to develop an EBV vaccine and 
the long history of safe adoptive T cell transfer to treat EBV associated malignancies 
suggest that this oncogenic -herpesvirus can be targeted by immunotherapies. Such 
vaccination should ideally implement the very same immune control that protects healthy 
EBV carriers. 
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1. Importance of EBV as a vaccination target  
The Epstein Barr virus (EBV) is a common human -herpesvirus with the most potent 
host cell transforming capacity of all infectious disease agents in vitro (1). It was 
discovered 55 years ago in Burkitt lymphoma (2, 3) and is associated with epithelial, 
lymphocyte and smooth muscle derived tumors in humans (4). The most prominent EBV 
associated tumors are in addition to the still most common Sub-Saharan childhood 
tumor Burkitt’s lymphoma, post-transplant lymphoproliferative disease (PTLD), diffuse 
large B cell lymphomas (DLBCL), Hodgkin’s lymphoma, nasopharyngeal carcinoma and 
the 10% of gastric carcinoma that are positive for this virus (5). Around 2% of all 
malignancies in humans are associated with EBV with an annual incidence rate of 
200’000 (6). In addition to these EBV associated malignancies, this virus causes 
immune pathologies that result from a hyperactivation of EBV induced T cell responses 
(7). These include syndromes that result from CD8+ T cell lymphocytosis during 
symptomatic primary EBV infection called infectious mononucleosis (IM) (8), from virus 
induced cytokine production for the hyperactivation of myeloid cells resulting in 
hemophagocytic lymphohistiocytosis (HLH) (9) and possibly also the autoimmune 
disease multiple sclerosis (MS) (10). Along the lines of EBV possibly setting up a pro-
inflammatory environment in the brain of some MS patients, it was recently reported that 
encephalitis in at least one patient under immune checkpoint treatment blocking the 
inhibitory receptor PD-1 on T cells was associated with elevated EBV loads in blood and 
cerebrospinal fluid, as well as clonal expansion of T cells with EBV specific T cell 
receptors in the brain (11). Accordingly, loss of EBV specific T cell mediated immune 
control was observed upon PD-1 blockade in a preclinical model of EBV infection in mice 
with reconstituted human immune system components (HIS mice) (12). Thus, both EBV 
associated malignancies and immune pathologies justify the development of a vaccine 
against EBV, but which individual or combination of viral antigens should be targeted.  
 For the choice of vaccine antigen, the life cycle of EBV and its gene expression 
in the various virus associated diseases needs to be considered. EBV is primarily 
transmitted via saliva exchange and most likely crosses the mucosal epithelial cell 
barrier by transcytosis to infect B cells in submucosal secondary lymphoid tissues like 
tonsils (13, 14). In B cells EBV expresses latent viral gene products from its circularized 
and increasingly chromatinized multi-copy extrachromosomal DNA (15). Initial 
expression of 6 nuclear antigens (EBNAs) and 2 membrane proteins (LMPs) in the so 
called latency III program is curtailed with further B cell differentiation to just EBNA1, 
LMP1 and 2 (latency II) in germinal center B cells and to finally no viral protein 
expression in memory B cells (latency 0), the site of EBV persistence (16). In 
homeostatically proliferating memory B cells EBNA1 is transiently expressed as the only 
viral protein (latency I) (17). The latent EBV proteins drive B cell proliferation allowing 
dissemination of the virus in the human body. From the reservoir in memory B cells EBV 
can reactivate upon plasma cell differentiation (18), and then presumably amplifies virion 
production by lytic replication in epithelial cells for more efficient shedding into the saliva 
and further transmission (19). EBV associated pathologies originate from these different 
stages of the EBV life cycle. For example, PTLD and some DLBCL express latency III, 
Hodgkin and Burkitt lymphoma emerge from germinal centers with latency II or latency I, 
respectively, and early lytic EBV antigen specific CD8+ T cells expand mainly during IM. 
Furthermore, early lytic EBV antigen expression has recently been recognized to 
enhance virus associated tumor formation (1). These considerations identify latent and 
early lytic EBV antigens as promising candidates for vaccines, but also envelope 
proteins are explored as targets of neutralizing antibody responses that could curb 
transmission. 
 
2. Protective immune responses against EBV infection  
With the classes of EBV antigens that could be targeted for vaccination against EBV 
associated diseases in mind, the question arises which type of immune responses 
should be elicited. Information about protective immune responses against EBV can be 
gleaned from preclinical in vitro and in vivo models and clinical observations. Among the 
most informative clinical observations are primary immunodeficiencies that identify 
genetic lesions that predispose for EBV associated diseases (20, 21). These point 
towards cytotoxic lymphocytes as the main immune compartment that exerts immune 
control over EBV infection. The respective lymphocytes need to be positive for the 
cytotoxic granule machinery, including perforin, Munc13-4 and Munc18-2 (22-24). They 
need to carry the co-stimulatory molecules CD27, SLAM protein family members like 
2B4, 4-1BB and NKG2D, as well as the co-inhibitory CTLA-4 receptor in combination 
with the main activating receptors CD16 or the T cell receptor (25-35). Furthermore, they 
need to expand well after activation and depend on GATA2 and MCM4 for their 
differentiation (36-39). In contrast EBV specific immune control does not seem to 
depend on type I and II interferons, antibody production and MHC class II restricted T 
cell responses (20). Particularly the absence of EBV associated pathologies in patients 
with B+ hypogammaglobunemia and Ig class switch recombination deficiencies is 
surprising (40, 41). Furthermore, since MHC class II deficiencies do not predispose for 
complications with EBV infection (42, 43), MHC class I restricted helper T cell functions 
might compensate to maintain cytotoxic lymphocytes. These considerations point to 
CD8+ T cells, natural killer (NK), NKT and  T cells as pillars of EBV specific immune 
control. Indeed, all of these cytotoxic lymphocyte populations have been shown to 
restrict EBV infection in the preclinical model of HIS mice (44-49). In addition the EBV 
specific CD8+ T cells might have a particular PD-1+Tim-3+KLRG1+CXCR5+TCF-1+ and 
BATF3+ phenotype that allows them to control EBV infected B cells in germinal centers 
(12, 50, 51). These CD8+ T cells recognize predominantly latent and early lytic EBV 
antigens (7). T cell lines have also been adoptively transferred to treat EBV associated 
malignancies, initially primarily PTLD (52). With respect to individual antigens EBNA1, 
LMP1 and LMP2 specific T cell lines have proven clinically efficacious in EBV associated 
lymphomas and nasopharyngeal carcinoma (53-55). Interestingly, T cells with these 
specificities have also been infused into MS patients with some clinical success (56, 57). 
Lytic EBV replication is in addition targeted by early differentiated CD56dimNKG2A+KIR- 
partially CD16+ NK cells (45, 58, 59). Both CD8+ T cells and NK cells significantly 
expand during IM (8, 59-62). In addition to early differentiated NK cells V8V2 T cells 
are elevated in a subset of children (63). They preferentially respond to Burkitt 
lymphoma cells with a latency I EBV gene expression. Finally, NKT cells preferentially 
respond to Hodgkin lymphoma and nasopharyngeal carcinoma cell lines (64). Thus, 
while CD8+ T cells target all EBV latencies and early lytic EBV replication, NK, NKT and 
 T cells seem to restrict lytic, latency II and latency I EBV infection, respectively. These 
might be the cytotoxic lymphocyte compartments on which immune control of EBV 
infection depends and that should be stimulated by EBV specific vaccination.  
 
3. Recombinant viral vector vaccines  
 
Recombinant viral vector vaccines are live viruses that are engineered to express 
additional proteins, against which immune responses are desired  (65, 66). These 
vaccine platforms are relatively new and have several advantages over traditional 
vaccines. First, viral vector vaccines can induce a broad range of immune responses, in 
particularly CD8+ cytotoxic T lymphocyte (CTL) responses that are important in clearing 
virally infected and tumor cells. This contrasts with most of the existing vaccine 
formulations that are designed to elicit primarily a humoral antibody response. The viral 
vector infects target cells and leads to antigen expression in the cytosol, where it can 
gain easy access to the classical MHC class I processing pathway, and subsequent 
presentation of the resulting peptide epitopes on MHC class I molecules to stimulate an 
antigen-specific CD8+ CTL response. Second, viruses are naturally immunogenic and 
therefore adjuvants themselves as they express a range of pathogen-associated 
molecular patterns (PAMPs) to initiate an inflammatory response. This adjuvant effect is 
crucial for enhancing the protective immune response elicited by vaccines. Third, viral 
vector vaccines have a high gene transduction efficiency (67) and can deliver the 
antigens to different cell types depending on the tropism of the used viral vectors. 
Many different viral vectors have been developed to use as vaccine candidates, 
including poxviruses, adenoviruses and yellow fever virus (65). The choice of viral 
vectors for vaccine development mostly depends on the vector’s properties with respect 
to immunogenicity, safety and infectivity. Furthermore, the pre-existing immunity against 
the viral vectors in humans are often considered. Vaccinia virus and adenovirus are 
among the most widely used viral vectors, mainly due to their ability to induce antigen-
specific T cell responses. Currently many clinical trials are ongoing to test diverse viral 
vector vaccines in different disease settings, mainly infectious diseases (68, 69). 
The first EBV vaccine tested in humans used live recombinant vaccinia virus 
expressing the EBV membrane antigen BLLF1 (gp350) (70). While there were no 
significant EBV titer variations between vaccinated and unvaccinated adults, only 3 of 9 
vaccinated infants were infected with EBV within 16 months after vaccination compared 
to 10 out of 10 in the unvaccinated control. However, this vaccine platform is no longer 
accepted due to the risk of adverse effects (71). A safer alternative is the multiplication 
incompetent attenuated pox viral vector of modified vaccinia virus Ankara (MVA) (72, 
73). Indeed, a MVA vaccine encoding the EBV antigens EBNA1 and LMP2 (MVA-EL) 
has been developed as a therapeutic vaccine against EBV-positive cancer (74, 75). This 
vaccine has been evaluated for safety and immunogenicity in phase I clinical trials in 
EBV-positive nasopharyngeal carcinoma (NPC) patients. MVA-EL was well tolerated 
and there was an increase in T cell responses against at least one antigen after 
vaccination in 8 of 14 patients in the UK and 15 of 18 patients in Hong Kong. However, 
the therapeutic efficacy of the MVA-EL has yet to be shown. A recombinant adenovirus 
vector has also been developed to induce EBV-specific T cell responses. However, 
instead of using it as a direct vaccination, facing pre-existing adenovirus immunity, the 
respective vectors encoding LMP polyepitopes with or without EBNA1 were used to 
infect DCs or EBV-transformed B lymphoblastoid cell lines in vitro, in order to either 
expand EBV-specific T cells and infuse these back into patients or to adoptively transfer 
the infected DCs as cellular vaccination (55, 76-78). Considering the complexity of 
cellular vaccine approaches, adenovirus vectors that are shielded against preexisting 
immunity and encode EBV antigens should be explored for direct vaccination against 
EBV.                   
 
4. Heterologous prime-boost vaccination 
Early work on adenovirus vaccines used serotypes such as human adenovirus 5 (hAd5), 
but pre-existing immunity that can neutralize the viral vector is widespread in the human 
population, thus limiting its potency and hampering its clinical use. Chimpanzee 
adenovirus vectors were then developed to avoid this pre-existing neutralizing immunity 
(79, 80). Unfortunately, the immunogenicity of these vectors can establish neutralizing 
responses that limit its capacity for secondary injections, requiring the use of different 
viral vectors during boost vaccination. Indeed, heterologous prime-boost strategies using 
two antigen formulations have been regarded as an improved way of immunization (81, 
82). 
Different combinations of heterologous prime-boost vaccines have been tested in 
animal models and some are undergoing efficacy testing in clinical trials, mainly against 
infectious diseases (82-84). Among these, the combination of chimpanzee adenovirus 
and MVA has been shown to induce a strong CD8+ T cell response that correlates with 
efficacy in humans against a liver-stage malaria antigen (85). The same strategy has 
been applied to vaccine development against additional diseases, including hepatitis C 
virus (HCV), Ebola virus and prostate cancer (86-88). Our group has also demonstrated 
that adenovirus prime and MVA boost vaccination against EBNA1 is efficient in eliciting 
comprehensive CD4+ and CD8+ T cell responses which can translate into protection 
against EBV antigen expressing lymphomas (89).   
Though viral vectors generally elicit a higher magnitude of T cell responses, they 
are expensive to produce and usually take a long time to manufacture. In contrast to 
these, protein-based vaccines are generally safer and cheaper to produce. Our lab has 
developed a vaccine platform to deliver the EBV antigen EBNA1 to antigen presenting 
cells by fusing the antigen to a monoclonal antibody against the DC endocytic receptor 
DEC-205 (90-92). This recombinant protein vaccine, adjuvanted with the double-
stranded RNA polyI:C, has been shown to induce robust T cell responses, but mostly 
CD4+ T cell responses and lacking CD8+ T cell responses when tested in vivo (89, 91). 
As viral vector vaccines are known for their superiority in inducing CD8+ T cell 
responses, we combined this approach with viral vector vaccines in order to stimulate 
strong CD4+ and CD8+ T cell responses (89). We have showed that this heterologous 
prime boost vaccination strategy is more efficient in inducing a protective T cell response 
than the homologous prime boost. The combination of the protein vaccine targeting 
DEC-205 and the adenovirus is only slightly less efficient than the adenovirus prime and 
MVA boost in protecting mice from T cell lymphoma challenge, with the later, however, 
being superior against B cell lymphomas. These findings are consistent with previous 
studies, indicating that human immunodeficiency virus (HIV) antigen targeting to DEC-
205 had to be boosted with a recombinant poxviral vaccine to elicit protective responses 
in nonhuman primates (93). Thus, heterologous prime-boost approaches should be 
considered in the future for the development of a vaccine against EBV that aims to elicit 
T cell mediated immune control.  
5. Virus-like particles  
Virus-like particles (VLPs) are defined as virus particles which do not contain any viral 
nucleic acids. The research efforts of the last decades led to the development of VLP 
vaccines, including human papillomavirus VLPs against cervical carcinoma and 
Plasmodium falciparum antigen displaying Alfalfa mosaic virus VLPs against malaria 
(94, 95). Because of their safety attributes and their ability to elicit virus-specific innate 
and adaptive immune responses without harming the host, VLPs were also investigated 
as versatile tools for EBV vaccine development.  
In 2015, a novel Newcastle disease virus (NDV) VLP platform displaying the 
EBVgp350/220 ectodomain was shown to elicit strong, long-lasting neutralizing antibody 
responses in BALB/c mice, which were, however, not significantly higher than responses 
induced by soluble gp350/220 (96). The NDV VLP platform was subsequently used to 
incorporate additional EBV envelope and latent antigens. The combination of gH/gL-
EBNA1 and gB/LMP2 into VLPs both led to the generation of high neutralizing titers and 
EBV-specific T-cell responses in vaccinated BALB/c mice (97). A different, but possibly 
even more promising approach, is to use VLPs based on the EBV particle. In order to 
reduce oncogenicity of EBV for vaccination, genetic elements and/or proteins involved in 
DNA packaging were deleted (98). Already 20 years ago, the first generation of cell lines 
that produce EBV VLPs were created by removing the terminal repeats (TRs), which 
previously had been identified as packaging signals of EBVs DNA (99-101). Those first 
EBV VLPs were able to bind human B and epithelial cells and did contain large amounts 
of viral particles, but no viral DNA. In 2011, Ruiss et al. developed EBV-derived VLPs in 
which the deletion of TRs was complemented with the deletion of potential EBV 
oncogenes namely EBNA2, 3A, 3B and 3C, LMP1 and BZLF1 for additional safety (102). 
Those EBV VLPs were shown to be assembled and released via the endosomal sorting 
complex for transport (ESCRT). Infected B cells were capable of presenting multiple 
EBV antigens to CD8+ and CD4+ T cells, which led to significant T cell expansions in 
vitro. In immunized BALB/c mice, the EBV VLPs elicited EBV specific humoral and 
cellular immune responses (102). 
Despite strong evidence of immune activation and a good safety profile in mice, 
the risk of remaining infectious oncogenic genomes in the early EBV VLPs remained 
high. Therefore, the development of EBV VLPs was further improved through the 
deletion of the viral packaging and nuclear egress proteins BFLF1/BFRF1A or the portal 
protein BBRF1 for viral DNA insertion into the capsid. In 2012, Pavlova et al. managed 
to create fully DNA free EBV VLPs. The BFLF1/BFRF1A mutant EBV strain elicited 
comparable CD4+ T cell responses as the EBV wildtype in vitro (103). Through these 
deletions the pathogenic potential of the EBV VLPs was reduced, however the 
responses against structural and lytic components of EBV may not be sufficient for the 
creation of an effective EBV vaccine.   
Therefore, more immunogenic EBV VLPs were created by fusing latent antigens 
such as EBNA1 and EBNA3C to the abundant major tegument protein BNRF1. Through 
this approach the EBV VLPs were able to stimulate potent CD4+ T cell responses 
against structural as well as latent EBV epitopes. In ex vivo cultures with human 
peripheral blood mononuclear cells, the EBV VLPs, which contained EBNA1 latent EBV 
antigen, could inhibit the outgrowth of EBV infected B cells more proficiently than their 
counterparts without latent antigen. This partial inhibition of EBV infection in B cells 
could also be shown in vivo in HIS mice, while 100% of the PBS-treated mice got 
infected after EBV challenge, only 14% of the VLP-EBNA1-immunized mice had 
detectable viral loads in their peripheral blood (104). Therefore, EBV derived VLPs might 
need to contain latent antigens in addition to the structural proteins to elicit protective 
immune responses. Despite the improved safety profile of EBV derived VLPs 
themselves, the low titers of these that can be produced by most cell lines and 
contaminants in the respective preparations that derive from the human producer cells 




6. Envelope protein formulations to elicit neutralizing antibodies  
Gp350/220 is an EBV glycoprotein, which initiates the attachment of EBV to susceptible 
host, primarily B cells expressing the complement receptor type 2 (CD21) and/or type 1 
(CD35) (105). Binding is further strengthened by the gp42 envelope protein interacting 
with MHC class II (106). While these glycoproteins are specific for EBV, fusion of the 
viral envelope with cellular membranes is finally mediated by the gH/gL and gB proteins 
that are conserved among the herpesviruses (107). Being crucial in the first step of EBV 
latent infection, gp350/220 is one of the antigenic candidates often in the focus of 
exploration for the development of a prophylactic EBV vaccine. In the past, multiple 
potent antibodies against the EBV gp350 protein were found in human blood (108). The 
neutralizing antibody that has been mainly characterized is the monoclonal 72A1 
antibody. The broad interest in the 72A1 antibody led to the development of a 
humanized anti-gp350 antibody which blocked EBV infection of B cells in vitro to 
equivalent levels as the mouse-human chimeric 72A1 antibody construct (109). 
However, immunizing with the gp350 protein alone did not lead to a prevention of 
infection with EBV in a phase II clinical trial, but only to a partial reduction of acute IM 
(110, 111). Therefore, improvements of the gp350 protein vaccination were conceived 
(112) and dimers, trimers and tetramers of gp350 elicited significantly higher neutralizing 
antibody titers in mice (113, 114). Multimerized gp350 therefore seems to elicit more 
potent B cell responses. 
Improvement of gp350 protein vaccines was not only achieved by 
multimerization, but also by the addition of immune stimulating adjuvants. A study of 
Heeke et al. included the use of GLA/SE as an adjuvant in addition to the vaccination 
with gp350 in mice and rabbits. GLA/SE is composed of the synthetic TLR4 agonist 
glucopyranosyl lipid A (GLA) integrated into a stable emulsion (SE). Mice and rabbits 
that were vaccinated with GLA/SE-adjuvanted gp350 vaccines showed elevated EBV-
neutralizing antibody titers. Also, high IgG titers and robust anti-gp350 CD4+ T cell 
responses could be detected in vaccinated mice (115). Furthermore, by epitope 
mapping, it was found that the immune response against EBV’s gp350 protein is mainly 
directed against one dominant neutralizing epitope of gp350. In an approach to focus the 
antibody response on this potent epitope, gp350 mimetic peptides with strong ionic, 
electrostatic or hydrogen bonds to the neutralizing region of the monoclonal antibody 
72A1 (116) were generated by computer modeling (117). In mice, those gp350 mimetic 
peptides elicited antibody responses that were able to block the interaction of 72A1 
antibody and gp350. This technique may lead to more potent peptide vaccines which 
could contain the neutralizing epitopes of multiple EBV envelope glycoproteins.  
 In addition to improving EBV gp350 specific vaccination, antigen formulations 
have been extended to the other envelope proteins. Cui et al. compared the vaccination 
of rabbits with recombinant monomeric as well as multimeric EBV gH/gL and gB proteins 
to gp350 protein vaccines. The group found that vaccination with EBV gH/gL or gB 
protein vaccines elicited higher neutralization titers than gp350 protein vaccines (118). 
These antibody titers were even increased when gH/gL and gB proteins were 
multimerized. Recently, Snijder et al. also used the proteins from the EBV fusion 
machinery as targets and the group isolated neutralizing human antibodies from memory 
B cells (119). An anti-gH/gL antibody, AMMO1, showed potent inhibition of infection of B 
and epithelial cells in vitro. Therefore, vaccination for gp350 plus the herpesviral fusion 
complex might elicit the most comprehensive humoral immune responses to EBV, 
Another promising approach for EBV vaccination, which also mainly focuses on 
the generation of neutralizing antibodies against viral glycoproteins, is the use of 
nanoparticles for the delivery of mutimerized and optimally spaced EBV antigens. In 
2015, nanoparticles containing a portion of the ectodomain of gp350 including the 
complement receptor 2 binding site were used to vaccinate mice and monkeys (120). 
Vaccinated mice developed anti-gp350 titers that were about 1000-fold higher than in 
mice that received a soluble monomeric gp350 vaccine and were protected against a 
challenge with vaccinia virus expressing gp350. Cynomolgus macaques immunized with 
the gp350 nanoparticles also generated anti-gp350 titers that were 3- to 10-fold higher 
than with soluble monomeric gp350 protein (120). More recently, the same group 
investigated the immunization of non-human primates with gH/gL- and gH/gL/gp42-
based nanoparticles. Those highly immunogenic vaccines elicited virus-neutralizing 
antibody responses that were maintained for at least 3 months after vaccination. It could 
be shown that the vaccination-induced antibodies were able to inhibit the viral fusion with 
B and epithelial cells (121). Because the vaccinated animals cannot be infected with 
EBV, it remains unclear whether these neutralizing antibody titers would inhibit EBV 
infection in vivo. 
 
7. Conclusions and outlook  
From the many approaches summarized above, it is clear that the time is ripe for 
vaccination against EBV associated pathologies. From the frequent reinfections of 
healthy virus carriers with EBV (122, 123) it seems also clear that sterilizing immunity 
against EBV infection is probably utopic. Such immune protection would also have to be 
watertight, because if it would be transient and just delay primary EBV infection, the 
ensuing initial encounters with the virus would carry a higher risk for IM (8). Therefore, 
establishing or maintaining immune control of asymptomatic persistent EBV infection 
should probably be the goal for EBV vaccination. In patients with already established 
EBV associated malignancies therapeutic vaccination might be an uphill battle. 
Furthermore, prophylactic vaccination against these pathologies might be difficult to 
assess in initial clinical trials due to their low incidence rate, usually ranging below 50 per 
100’000 individuals (4). Therefore, the most likely scenario to test EBV specific vaccine 
candidates are adolescents or young adults that are still EBV seronegative (around one 
third of this population) and who have a high risk to acquiring EBV with IM (30-50%) (8), 
followed by an increased risk for Hodgkin lymphoma and MS (124, 125). Even so natural 
immune control of EBV primarily relies on cytotoxic lymphocytes (20, 21), vaccine 
induced EBV neutralizing antibodies could convert IM into asymptomatic infection, 
because the elevated viral shedding into the saliva and CD8+ T cell lymphocytosis driven 
by early lytic EBV antigens suggest that uncontrolled lytic replication contributes to IM 
(7). Therefore, all the above discussed EBV vaccine candidates could prevent IM and 
provide the proof of concept that immunization against EBV is possible. In the end, 
however, vaccination or the endogenous immune response to asymptomatic EBV 
infection probably needs to establish long-lived immune control by cytotoxic CD8+ T 
cells, which form the required cornerstone of natural immunity to this tumor virus. Thus, 
the development of an EBV specific vaccine offers the possibility to design formulations 
that selectively elicit such cell-mediated immune control, which then also could be 
adapted to tumors that are not associated with viruses. 
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Figure legend 
Figure 1: EBV vaccine candidates. EBV specific vaccination aims to either stimulate 
protective T cell responses (top half) or neutralizing antibodies (bottom half), that target 
latent and lytic EBV infected B cells or prevent B and epithelial cell infection, 
respectively. For EBV specific T cell stimulation, recombinant adenoviruses encoding 
latent EBV antigens are explored for dendritic cell infection, followed by T cell expansion 
in vitro for adoptive transfer or injection into patients with EBV associated malignancies. 
Furthermore, latent EBV antigen targeting to dendritic cells with antibodies is 
investigated. Moreover, recombinant modified vaccinia virus Ankara (MVA) vectors 
expressing latent EBV antigens have been developed and tested in patients. Finally, 
EBV derived virus like particles (VLPs) have shown promising results in preclinical 
models, lowering EBV titers when a latent EBV antigen was transgenically expressed in 
the viral tegument. Neutralizing antibodies were also elicited with VLPs or EBV envelope 
proteins. These antibody responses were more potent after multimerization of the 
respective glycoproteins or their incorporation into nanoparticles. This figure was created 
in part with modified Servier Medical Art templates, which are licensed under a Creative 
Commons Attribution 3.0 Unported License: https://smart.servier.com. 
 
 
 
 

